Developing a Combined Molecular Screening and Triage Test for Cervical Cancer Based on Human Papillomavirus (HPV) Detection, Quantification, Genotyping and DNA Methylation in Self-samples (COMBISCREEN)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Detection of (epi)genetic biomarkers for cervical cancer and precancer
研究概览
简要总结
The goal of the COMBISCREEN project is to develop a fully molecular cervical screening and triage approach that is applicable on self-samples, which are an easily accessible and non-invasive source of biomarkers. The project allows a one-step screening and triage modality and thereby identifies women with clinically relevant disease that are in need of treatment.
详细描述
Currently, there is still 37% of the Flemish population eligible for cervical cancer screening that remains un(der)screened. Self-collected urine and vaginal samples that can be collected from home and are non-invasive provide an attractive alternative for this group. The aim of this study is to collect different samples from patients with a cervical cancer or a scheduled conization in order to identify potential biomarkers for cervical cancer and cervical intraepithelial neoplasia (CIN). These samples include a home-collected first-void urine (Colli-Pee 20mL prefilled with urine conservation medium (UCM)) and vaginal self-sample (Evalyn Brush), as well as a clinician collected cervical smear, blood sample and when appropriate also a tissue sample. A tissue sample will only be collected when the patient is undergoing surgical procedures for their standard therapy. As such, they do not undergo additional invasive procedures as part of the study. The samples are collected prior to starting therapeutic processes (e.g. conization, chemotherapy, radiotherapy, surgery...). The presence of biomarkers (e.g. human papillomavirus (HPV) and DNA methylation) for cervical cancer and cervical intraepithelial neoplasia (CIN) will be determined and compared in each of the sample types. The results of the biomarker assays will also be compared to clinical results from cytology and histology in order to determine the accuracy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 64 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •25 until 64 years old
- •Diagnosed with cervical cancer (CIN3+, irrespective of stage) OR in need of conization (irrespective of diagnostic or therapeutic purposes)
- •Has not started any form of cancer treatment prior to study enrollment
- •Written informed consent must be obtained from patient
- •Is able to understand the information brochure and what the study is about
排除标准
- •Women that underwent hysterectomy
- •Pregnant women or 6 weeks post-partum
- •Treatment for cervical (pre)cancer in the last 6 months before participation in the study
- •Participating in another interventional clinical study (where e.g., a medical device, drug, or vaccine is evaluated) at the same time of participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.
- •Unable to give informed consent
- •Patient has severe anaemia
- •Patient received blood transfusion two weeks before sample collection
- •Blood sampling would compromise patients' overall health
- •Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C.
- •Patients who are alcoholic or drug abusers
- •Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator.
结局指标
主要结局
Detection of (epi)genetic biomarkers for cervical cancer and precancer
时间窗: 48 months
A novel assay will be developed for the detection of the human papillomavirus (HPV) and epigenetic biomarkers to determine the presence of cervical (pre)cancer. Using histology outcomes as a reference test.
次要结局
- Comparison of the biomarkers detected in the different sample types.(48 months)
- Demonstrate non-inferiority of the biomarker assay in self-samples compared to conventional cytology on pap smears.(48 months)
- Determine the predictive value of the biomarker assay and the long-term risk of cervical (pre)cancer(Within 1 year after study completion)
研究者
Wiebren Tjalma
principal investigator
Universiteit Antwerpen